Pennsylvania is currently home to 3309 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluating the Durability of Closure for Venous Leg Ulcers
NCT06697925
Recruiting
The goal of this observational study is to determine the durability of closure for venous leg ulcer subjects that achieved closure in the THOR trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Serena Group, Monroeville, Pennsylvania
Conditions: Venous Leg, Venous Leg Ulcer (VLU), Venous Leg Ulcer, Venous Ulcer, VLU
Register for Updates
Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers
NCT06693570
Recruiting
The purpose of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of hard-to-heal venous leg ulcers (VLU) between Intact Fish Skin Graft plus standard of care (IFSG/SOC) versus standard of care alone (SOC) over 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Serena Group- Monroeville, Monroeville, Pennsylvania
Conditions: Venous Leg Ulcer (VLU), Venous Leg Ulcers, Venous Leg, Nonhealing Venous Leg Ulcer
Register for Updates
BINGO: Bridging Knowledge, Increasing Awareness
NCT06504407
Recruiting
The U.S. population is becoming more diverse, but minority groups are still significantly underrepresented in cancer clinical trials. This disparity limits our understanding of how treatments work across different populations. Efforts like the 21st Century Cures Act aim to improve inclusion, but challenges persist due to historical mistrust and complex barriers in healthcare. To address these issues, Penn State Health is using a fun and educational approach called "BINGO" to engage the African... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Penn State Cancer Institute, Hershey, Pennsylvania
Conditions: Cancer Education, Health Equity
Register for Updates
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - a Randomized Clinical Trial in Acute Kidney Injury
NCT05758077
Recruiting
This randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) when compared to CKRT alone (standard of care). This study is further intended to determine whether SCD therapy will reduce the duration of maintenance dialysis secondary to AKI. This study will enroll approximately 200... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: St Luke's University Hospital, Bethlehem, Pennsylvania
Conditions: Acute Kidney Injury
Register for Updates
A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD
NCT05643638
Recruiting
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Penn State Health, Hershey, Pennsylvania
Conditions: Graft Versus Host Disease, Acute
Register for Updates
Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects
NCT05239793
Recruiting
This is a pilot study on the impact of switching from cigarettes to Electronic Cigarettes (EC) on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting Chronic Obstructive Pulmonary Disease (COPD). The researchers hypothesize that the smokers who switch to EC completely or significantly will experience reduced COPD symptoms, risks of exacerbations, and decreased levels of oxidative stress and inflammation.
Gender:
ALL
Ages:
Between 21 years and 74 years
Trial Updated:
01/22/2025
Locations: Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Validation of Oxygen Nanosensor in Mitochondrial Myopathy
NCT04086329
Recruiting
Past mitochondrial disease treatment studies have been unsuccessful in determining treatment efficacy, and a major factor has been the lack of validated biomarkers in mitochondrial myopathy (MM). There is currently a growing number of potential new treatments to be tested through MM clinical intervention trials, which has created a pressing need for quantitative biomarkers that reliably reflect MM disease severity, progression, and therapeutic response. The purpose of the study is to measure th... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/22/2025
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Mitochondrial Myopathies, Mitochondrial Diseases
Register for Updates
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
NCT03760575
Recruiting
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Mesotheliomas Pleural
Register for Updates
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
NCT06568367
Recruiting
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Wyomissing, Pennsylvania
Conditions: Excessive Sleepiness, Shift-work Disorder
Register for Updates
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06413433
Recruiting
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Allentown, Pennsylvania
Conditions: Binge-Eating Disorder
Register for Updates
Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation
NCT06364215
Recruiting
The purpose of this study is to compare the efficacy and safety between pulmonary vein isolation (PVI) alone versus PVI with left atrial (LA) posterior wall isolation (PWI) using pulsed-field ablation (PFA) in the treatment of patients with paroxysmal atrial fibrillation (PAF).
Gender:
ALL
Ages:
Between 21 years and 90 years
Trial Updated:
01/21/2025
Locations: Doylestown Hospital, Doylestown, Pennsylvania
Conditions: Atrial Fibrillation Paroxysmal
Register for Updates
A Study with L19TNF in Combination with Lomustine in Patients with Glioblastoma At Progression or Recurrence
NCT06336291
Recruiting
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Glioblastoma
Register for Updates